Growing field of Personalized Medicine

After completing our new report on the Personalized Medicine market we decided to take a look at identifying some of the Institutes that have been established. Many organizations have entered this promising field. Some of these include:

The International Rare Disease Research Consortium invites public and private partners from across the globe with shared commitment to join its efforts to alleviate the suffering of individuals affected by diseases for which today there are no treatments available. The group will next develop the scientific and policy framework to guide research activities and to foster collaboration among stakeholders to explore systematically all venues to accelerate the development of diagnostics and therapies for rare diseases.

The National Institutes of Health this fall will open a center to speed genetic discoveries into usable therapies, doing some of the riskiest early-stage research in hopes companies then will step in.

The Charles R. Bronfman Institute for Personalized Medicine explores how genetic information and environmental exposure affect each person’s risk to develop certain diseases and response to medication. The Institute examines how this new model of genome-informed personalized healthcare may be translated in clinical settings to advance the practice, delivery and economics of health care.

Cleveland Clinic’s Center for Personalized Healthcare will initially focus on offering health providers tools that will tailor care plans to patients’ individual characteristics.

With the establishment of a pioneering Genomic Medicine Institute, El Camino Hospital stands poised to develop the nation’s first community hospital based center of excellence focused on ushering the promise of personalized medicine from the research laboratory to patients, spurring genomic medicine to become the new standard of care.

The Coriell Personalized Medicine Collaborative^® (CPMC^®) is a longitudinal research study designed to determine the utility of using personal genome information in health management and clinical decision-making. The CPMC^® also aims to discover presently unknown gene variants that elevate one’s risk of complex disease and affect one’s response to medications.

Fox Chase’s new Institute for Personalized Medicine is on the forefront of a transformation in cancer care. Unlike the traditional method of delivering care, this approach will base treatment on the genetic makeup of an individual patient’s tumor, making the “one-size-fits-all” approach to cancer therapy a thing of the past.

Indiana University has announced a major commitment to research in one of health care’s most promising fields with the creation of the Indiana Institute for Personalized Medicine. The institute’s members will be drawn from the IU schools of medicine, informatics and nursing, with $11.25 million in funding.

Inova Translational Medicine Institute (ITMI) is a not-for-profit research institute delving into the next frontier of healthcare innovation: personalized medicine. Personalized medicine is a medical model that emphasizes the customization of healthcare to individual patients. It involves the use of genetic information about an individual patient.

Johns Hopkins University officials said hat they will use a $30 million gift from a former student to build a home for a center for personalized medicine, a growing field that uses genetic information to tailor treatments for cancer and other ailments.

The Ohio State University Medical Center (OSUMC) has made it a priority to develop a leadership position nationally in personalized health care. The Medical Center’s Strategic Plan calls for each of its six Signature Programs (Cancer, Critical Care, Heart, Imaging, Neurosciences, Transplantation) and three Support Programs (Behavioral Medicine, Bioinformatics, Genetics) to develop, support, and implement initiatives that bring personalized health care to a practical reality.

Harvard Medical School (HMS) and Partners HealthCare System (PHS) established the Harvard-Partners Center for Genetics and Genomics (HPCGG) in 2001. The Center was launched in recognition of the excitement of the Human Genome Project and as an early commitment to the importance that genetic and genomic knowledge would play in human health.

The Stanford University Medicine Genome Technology Center develops new technologies to address important biological questions that otherwise would not be feasible.

Vanderbilt-Ingram Cancer Center (VICC) has launched its new Personalized Cancer Medicine Initiative, becoming the first cancer center in the Southeast and one of the first in the nation to offer cancer patients routine “genotyping” of their tumors at the DNA level.

The Center for Genomics and Personalized Medicine Research at Wake Forest School of Medicine provides a key role in supporting facilitation of investigators, providing educational programs, clinical genomic trials to predict patient response to therapy, personalize therapy and design preemptive and new strategies.